Ivermectin as a Potential Addition to the Limited Anti-COVID-19 Arsenal: A Double-Blinded Clinical Trial
| Author | Mehran Varnaseri | en |
| Author | Fatemeh Amini | en |
| Author | Ramin Jamshididan | en |
| Author | Mehrdad Dargahi | en |
| Author | Nematollah Gheibi | en |
| Author | Sara Abolghasemi | en |
| Author | Mohammadreza Dayer | en |
| Author | Negar Varnasseri | en |
| Author | Khojasteh Hoseinynejad | en |
| Author | Sahar Kheradhoosh | en |
| Author | Pedram Nazari | en |
| Author | Ebrahim Babadi | en |
| Author | Seyedeh Maryam Mousavinezhad | en |
| Author | Pouya Ebrahimi | en |
| Orcid | Mehran Varnaseri [0000-0002-5863-487X] | en |
| Orcid | Mehrdad Dargahi [3359-4449-0002-0000] | en |
| Orcid | Nematollah Gheibi [0000-0001-7503-0894] | en |
| Orcid | Sara Abolghasemi [0000-0001-7117-6079] | en |
| Orcid | Seyedeh Maryam Mousavinezhad [0000-0002-9636-652X] | en |
| Orcid | Pouya Ebrahimi [0009-0005-3694-6863] | en |
| Issued Date | 2024-04-30 | en |
| Abstract | Background: Addressing the Coronavirus disease 2019 (COVID-19) pandemic remains a significant challenge for healthcare systems globally. Despite the absence of a proven cure, ivermectin has been proposed as a potentially effective agent against it. Objectives: This study aimed to evaluate the therapeutic effects of ivermectin compared to a placebo group in non-critically ill confirmed COVID-19 patients. Methods: A double-blind, randomized clinical trial was conducted on 110 patients with moderate-to-severe (non-critical) confirmed COVID-19 infection. The patients were equally divided into two groups, with one group receiving ivermectin tablets (14 mg every 12 hours for three days) and the other group receiving a placebo. The efficacy and safety of ivermectin were assessed in both groups. Results: A total of 110 patients, including 62 (56.4%) men and 48 (43.6%) women, with an average age of 53.36 ± 15.10 years, were enrolled in our double-blind, randomized clinical trial. The baseline characteristics of the two groups were similar. The findings demonstrated that ivermectin significantly reduced the need for Intensive Care Unit admission (32.7% vs. 5.5%; P < 0.001), hospitalization duration (six vs. four days; P < 0.001), and median time to symptom resolution period (P < 0.05) in COVID-19 patients compared to the placebo group, without any serious side effects (P > 0.05). Conclusions: Ivermectin appears to be a potentially effective and safe medication for COVID-19 patients with moderate disease. | en |
| DOI | https://doi.org/10.5812/jjhs-146703 | en |
| Keyword | COVID-19 | en |
| Keyword | Ivermectin | en |
| Keyword | Treatment Efficacy | en |
| Keyword | Drug Safety | en |
| Keyword | Randomized Controlled Trial | en |
| Publisher | Brieflands | en |
| Title | Ivermectin as a Potential Addition to the Limited Anti-COVID-19 Arsenal: A Double-Blinded Clinical Trial | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jjhs-16-2-146703-publish-pdf.pdf
- Size:
- 201.36 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF